Wells Fargo set a $39.00 price objective on Flexion Therapeutics (NASDAQ:FLXN) in a report issued on Tuesday morning. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.
Several other equities analysts have also issued reports on the stock. BidaskClub lowered shares of Flexion Therapeutics from a sell rating to a strong sell rating in a report on Saturday, January 20th. Berenberg Bank initiated coverage on shares of Flexion Therapeutics in a report on Thursday, February 1st. They issued a buy rating and a $42.00 price target on the stock. ValuEngine raised shares of Flexion Therapeutics from a sell rating to a hold rating in a report on Sunday, December 31st. Zacks Investment Research lowered shares of Flexion Therapeutics from a hold rating to a sell rating in a report on Tuesday, January 30th. Finally, BMO Capital Markets reaffirmed an outperform rating and issued a $36.00 price target (down from $37.00) on shares of Flexion Therapeutics in a report on Friday, March 9th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus price target of $99.00.
NASDAQ FLXN traded down $0.10 on Tuesday, hitting $23.52. The stock had a trading volume of 110,598 shares, compared to its average volume of 774,181. The company has a current ratio of 13.02, a quick ratio of 12.96 and a debt-to-equity ratio of 0.58. Flexion Therapeutics has a 52-week low of $16.51 and a 52-week high of $32.25. The firm has a market capitalization of $937.85, a P/E ratio of -5.65 and a beta of 0.83.
Several institutional investors and hedge funds have recently made changes to their positions in FLXN. Wells Fargo & Company MN grew its holdings in shares of Flexion Therapeutics by 1,024.1% during the fourth quarter. Wells Fargo & Company MN now owns 1,706,942 shares of the specialty pharmaceutical company’s stock valued at $42,742,000 after buying an additional 1,555,093 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Flexion Therapeutics by 17.4% during the fourth quarter. BlackRock Inc. now owns 2,650,986 shares of the specialty pharmaceutical company’s stock valued at $66,381,000 after buying an additional 392,055 shares during the last quarter. Perceptive Advisors LLC purchased a new stake in shares of Flexion Therapeutics during the fourth quarter valued at $7,712,000. Ardsley Advisory Partners grew its holdings in shares of Flexion Therapeutics by 137.1% during the fourth quarter. Ardsley Advisory Partners now owns 415,000 shares of the specialty pharmaceutical company’s stock valued at $10,392,000 after buying an additional 240,000 shares during the last quarter. Finally, American Financial Group Inc. purchased a new stake in shares of Flexion Therapeutics during the fourth quarter valued at $5,280,000. 94.46% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “Flexion Therapeutics (FLXN) PT Set at $39.00 by Wells Fargo” was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3335321/flexion-therapeutics-flxn-pt-set-at-39-00-by-wells-fargo.html.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.